Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Marion-Gabriele Ott"'
Autor:
John Mascarenhas, Marina Konopleva, Michael Andreeff, Cristina Papayannidis, Andrew H. Wei, Naval Daver, Marion Gabriele Ott, Giovanni Martinelli, Brian Higgins
Publikováno v:
Leukemia. 34:2858-2874
Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2 represents an attractive treatment approach for cancers with wild-type or functional TP53. Indeed, several small molecules have been developed and evaluated in various mali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c899426f68b8de5617b820ef5c0a7c
https://doi.org/10.1038/s41375-020-0949-z
https://doi.org/10.1038/s41375-020-0949-z
Autor:
S. Muehlbauer, Karen Seiter, Margaret Kasner, Gwen Nichols, Annabelle Monnet, Jianguo Zhi, Marion Gabriele Ott, Kevin R. Kelly, Silke Simon, William E. Pierceall, Sarit Assouline, Michael Dickinson, Sung-Soo Yoon, Lin-Chi Chen, Mark Drummond, Cristina Papayannidis, Norbert Vey, Karen W.L. Yee, Je-Hwan Lee, Giovanni Martinelli, Lori Jukofsky, Steven Blotner, Brian Higgins
Publikováno v:
Leukemia research. 100
The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid leukemia; thus, novel therapies are needed. We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or with cytarabine in patients with r/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e080b3af3a5b19ba7db74059dd50002
https://pubmed.ncbi.nlm.nih.gov/33302031
https://pubmed.ncbi.nlm.nih.gov/33302031
Autor:
Marion Gabriele Ott, David Oppenheim, L. Andries, Friedrich Feuerhake, S. Soehrman Brossard, Mark McGurk, Stéphane Temam, Jérôme Sarini, Paul Delmar, Christoph Mancao, Luigi Manenti, Stefan Evers, Jean-Charles Soria, K. Hussain, Jean-Pierre Delord, Alexandre Passioukov, L. Di Scala, Antoine Hollebecque, James Spicer, Farzin Farzaneh
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 28(11)
Background In addition to inhibiting epidermal growth factor receptor (EGFR) signaling, anti-EGFR antibodies of the IgG1 'subtype' can induce a complementary therapeutic effect through the induction of antibody-dependent cell-mediated cytotoxicity (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99d8bdd86eaf7f03ca3b4b8c1948fe0
https://pubmed.ncbi.nlm.nih.gov/28950289
https://pubmed.ncbi.nlm.nih.gov/28950289
Autor:
Pierre Fenaux, Jacqueline S. Garcia, Whitney P. Kirschbrown, Rebecca L. Olin, Gail J. Roboz, Daniel A. Pollyea, Norbert Vey, Michael Andreeff, Naval Daver, Marion Gabriele Ott, Marina Konopleva, Stefania Paolini, Arnaud Pigneux, Brian A. Jonas, Sarit Assouline, Giuseppe Visani, Cherie Green, Monique Dail, Giovanni Martinelli, Kevin R. Kelly, Bayard L. Powell, Karen W.L. Yee, Maika Onishi, Joseph Brandwein, Jue Wang, Agostino Tafuri, Wan-Jen Hong
Publikováno v:
Blood. 134:229-229
Introduction: Elderly pts with R/R AML not eligible for cytotoxic therapy have limited therapeutic options, and dismal outcomes with available therapies. In preclinical studies, inhibition of BCL-2 and MDM2 with Ven and Idasa, respectively, has demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8827743dde8e4b744fc959f7ba2dca79
https://doi.org/10.1182/blood-2019-123711
https://doi.org/10.1182/blood-2019-123711
Autor:
Oliver G. Ottmann, Marion Gabriele Ott, Norbert Vey, Annabelle Monnet, Andrew H. Wei, Marina Konopleva, Rebeca Rodríguez-Veiga, Pau Montesinos, Jordi Esteve, Giovanni Martinelli, Pierre Fenaux, Idy Chiu, Christoph Röllig
Publikováno v:
Journal of Clinical Oncology. 37:TPS7063-TPS7063
TPS7063 Background: The prognosis for patients (pts) with relapsed or refractory (R/R) acute myeloid leukemia (AML) is poor, with 3-year overall survival rates ~10–30% after intensive chemotherapy-based approaches. Despite the advent of targeted th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e78de1676d467521d886241f70fe3bcf
https://doi.org/10.1200/jco.2019.37.15_suppl.tps7063
https://doi.org/10.1200/jco.2019.37.15_suppl.tps7063
Autor:
Naval Daver, Karen W.L. Yee, Gail J. Roboz, Daniel A. Pollyea, Marion Gabriele Ott, Pierre Fenaux, Monique Dail, Marina Konopleva, Wan-Jen Hong, Norbert Vey, Whitney P. Kirschbrown, Rebecca L. Olin, Giuseppe Visani, Jue Wang, Mehrdad Mobasher, Jacqueline S. Garcia, Agostino Tafuri, Michael Andreeff, Sarit Assouline, Connie Ma, Brian A. Jonas, Cherie Green, Patrick Phuong
Publikováno v:
Blood. 132:767-767
Introduction Effective therapies for R/R AML remain limited. MEK or MDM2 inhibition can downregulate MCL1, overcoming resistance to BCL2 inhibition. Preclinical synergy was seen when combining BCL2 inhibitor Ven with MEK inhibitor cobimetinib (cobi)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::155d5071e67ebef0241259761a48d55c
https://doi.org/10.1182/blood-2018-99-116013
https://doi.org/10.1182/blood-2018-99-116013
Autor:
Desamparados Roda, Farzin Farzaneh, Josep Tabernero, Andrés Cervantes, Yann Berge, Jean-Pierre Delord, Alexandre Passioukov, David Oppenheim, Carlos Gomez-Roca, Luigi Manenti, Paul Delmar, Sophia Soehrman Brossard, Jean-Charles Soria, Rocio Garcia-Carbonero, Luis Paz-Ares, Marion Gabriele Ott, Jaume Capdevila
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(3)
Aim Imgatuzumab (GA201) is a novel anti-epidermal growth factor receptor (anti-EGFR) antibody glycoengineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the efficacy of imgatuzumab in patients with EGFR-positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48720e2b2d86ca3e6e04f1fe12dceffa
https://pubmed.ncbi.nlm.nih.gov/24262587
https://pubmed.ncbi.nlm.nih.gov/24262587
Autor:
Salvatore Siena, Cristina Nadal, Carles Pericay, Josep Tabernero, Andrew Strickland, John Bridgewater, Giuseppe Aprile, Rocio Garcia Carbonero, David Cunningham, Marion Gabriele Ott, Sophie Golding, Leslie Samuel, Andrés Cervantes, Daniel Hochhauser, Antonio Cubillo, Ben Markman, Cecile Guizani, Jose Alejandro Perez-Fidalgo, Vanesa Lopez Valverde, Darren Sigal
Publikováno v:
Journal of Clinical Oncology. 33:669-669
669 Background: Imgatuzumab, a humanized engineered IgG1 anti-Epidermal Growth Factor Receptor (EGFR) mAb designed to enhance ADCC, showed promising clinical activity in a phase I trial including KRAS MT mCRC. This multicenter phase II study (NCT0132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24f93c5f64747be89fb7771041aed8ac
https://doi.org/10.1200/jco.2015.33.3_suppl.669
https://doi.org/10.1200/jco.2015.33.3_suppl.669
Autor:
Marion-Gabriele Ott, Hans Martin, Dieter Hoelzer, Oliver G. Ottmann, Manuel Grez, Heike Bialek, Heike Merget-Millitzer, Reinhard Seger, Johann Peter Hossle, Nicole Brüggenolte
Publikováno v:
Journal of hematotherapystem cell research. 11(4)
As a single-gene defect in phagocytes, the X-linked form of chronic granulomatous disease (X-CGD) is a disorder potentially amenable to gene therapy by transfer of a functional copy of the gp91(phox) gene into hematopoietic stem cells (HSC). Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53795e327e71b4b123cff31597b803de
https://pubmed.ncbi.nlm.nih.gov/12201957
https://pubmed.ncbi.nlm.nih.gov/12201957
Publikováno v:
Cancer immunology, immunotherapy : CII. 42(1)
Tumor necrosis factor alpha (TNFalpha) and interferon gamma (IFNgamma) are important immunomodulators. They are capable of acting in a synergistic manner on tumor cells in vitro and in vivo. In a clinical phase I study 13 patients with malignant asci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae06d6be7465e29d3138201c2a3cd37
https://pubmed.ncbi.nlm.nih.gov/8625364
https://pubmed.ncbi.nlm.nih.gov/8625364